Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Chemotherapy
Elderly patients
Head-and-neck cancer
Head-and-neck squamous cell carcinoma
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
04 Feb 2020
04 Feb 2020
Historique:
received:
13
12
2019
accepted:
29
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
31
10
2020
Statut:
epublish
Résumé
Head-and-neck squamous cell carcinoma (HNSCC) is one of the most common malignancies globally, and the number of elderly patients diagnosed with HNSCC is increasing. However, as elderly HNSCC patients are underrepresented in clinical trials, current clinical decision making for this cohort largely lacks clinical evidence. Elderly patients (≥65 years) with HNSCC undergoing (chemo)radiotherapy from 2010 to 2018 at Freiburg University Medical Center were assessed for patterns of care, locoregional control (LRC), progression-free (PFS) and overall survival (OS) regarding definitive and adjuvant treatments. Acute and late therapy-associated toxicities were quantified according to CTCAE v5.0. Two hundred forty-six patients were included in this analysis, of whom 166 received definitive and 80 adjuvant treatment. Two-year rates for OS, PFS and LRC were 56.9, 44.9 and 75.5%, respectively. Survival differed significantly between age groups with an OS of 40 and 22 months and a PFS of 23 and 12 months for patients aged 65-74 or ≥ 75 years, respectively (p < 0.05). Concomitant chemotherapy resulted in improved OS in patients aged 65-74 years compared to radiotherapy alone (p < 0.05) for definitive treatments, while patients ≥75 years did not benefit (p = 0.904). For adjuvant chemoradiotherapy, a trend towards superior OS rates was observed for patients aged 65-74 years (p = 0.151). Low performance status (HR = 2.584, 95% CI 1.561-4.274; p < 0.001) and smoking (HR = 1.960, 95% CI 1.109-3.464, p < 0.05) were the strongest independent prognostic factor in the multivariate analysis for decreased OS. One hundred thirty-eight patients (56.1%) experienced acute grade 3/4 and 45 patients (19.9%) chronic grade 3 toxicities. Radiotherapy is a feasible treatment modality for elderly HNSCC patients. The relatively low OS compared to high LRC may reflect age and comorbidities. Concomitant chemotherapy should be critically discussed in elderly HNSCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Head-and-neck squamous cell carcinoma (HNSCC) is one of the most common malignancies globally, and the number of elderly patients diagnosed with HNSCC is increasing. However, as elderly HNSCC patients are underrepresented in clinical trials, current clinical decision making for this cohort largely lacks clinical evidence.
METHODS
METHODS
Elderly patients (≥65 years) with HNSCC undergoing (chemo)radiotherapy from 2010 to 2018 at Freiburg University Medical Center were assessed for patterns of care, locoregional control (LRC), progression-free (PFS) and overall survival (OS) regarding definitive and adjuvant treatments. Acute and late therapy-associated toxicities were quantified according to CTCAE v5.0.
RESULTS
RESULTS
Two hundred forty-six patients were included in this analysis, of whom 166 received definitive and 80 adjuvant treatment. Two-year rates for OS, PFS and LRC were 56.9, 44.9 and 75.5%, respectively. Survival differed significantly between age groups with an OS of 40 and 22 months and a PFS of 23 and 12 months for patients aged 65-74 or ≥ 75 years, respectively (p < 0.05). Concomitant chemotherapy resulted in improved OS in patients aged 65-74 years compared to radiotherapy alone (p < 0.05) for definitive treatments, while patients ≥75 years did not benefit (p = 0.904). For adjuvant chemoradiotherapy, a trend towards superior OS rates was observed for patients aged 65-74 years (p = 0.151). Low performance status (HR = 2.584, 95% CI 1.561-4.274; p < 0.001) and smoking (HR = 1.960, 95% CI 1.109-3.464, p < 0.05) were the strongest independent prognostic factor in the multivariate analysis for decreased OS. One hundred thirty-eight patients (56.1%) experienced acute grade 3/4 and 45 patients (19.9%) chronic grade 3 toxicities.
CONCLUSION
CONCLUSIONS
Radiotherapy is a feasible treatment modality for elderly HNSCC patients. The relatively low OS compared to high LRC may reflect age and comorbidities. Concomitant chemotherapy should be critically discussed in elderly HNSCC patients.
Identifiants
pubmed: 32019576
doi: 10.1186/s13014-020-1481-z
pii: 10.1186/s13014-020-1481-z
pmc: PMC7001207
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
31Références
Strahlenther Onkol. 1996 Sep;172(9):485-8
pubmed: 8830810
J Natl Cancer Inst. 1994 Dec 7;86(23):1766-70
pubmed: 7966414
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Clin Oncol. 2009 Apr 20;27(12):1969-75
pubmed: 19289626
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Lancet. 2006 Sep 2;368(9538):843-54
pubmed: 16950362
Biomed Res Int. 2018 Jan 17;2018:3508795
pubmed: 29581971
J Clin Oncol. 1988 Dec;6(12):1903-11
pubmed: 3058879
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):30-7
pubmed: 24725687
Head Neck. 2018 Jun;40(6):1228-1236
pubmed: 29417700
Oncologist. 2013;18(5):568-78
pubmed: 23635557
Medicine (Baltimore). 2016 May;95(20):e3728
pubmed: 27196494
Eur Arch Otorhinolaryngol. 2005 Jan;262(1):21-6
pubmed: 15014947
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):868-883
pubmed: 28602414
Head Neck. 2010 Jun;32(6):728-36
pubmed: 19827120
J Geriatr Oncol. 2013 Oct;4(4):327-33
pubmed: 24472475
Med Oncol. 2019 Mar 29;36(5):42
pubmed: 30927146
Ann Oncol. 1991 Jun;2(6):437-9
pubmed: 1768630
Radiother Oncol. 2014 Dec;113(3):317-23
pubmed: 25480095
Eur J Cancer. 1996 Nov;32A(12):2075-81
pubmed: 9014748
Ann Surg Oncol. 2007 Apr;14(4):1449-57
pubmed: 17235712
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Med Oncol. 2019 Jun 12;36(8):68
pubmed: 31190132
Laryngoscope. 2018 Apr;128(4):831-840
pubmed: 28833217
Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1619-21
pubmed: 20454970
Radiother Oncol. 2006 Apr;79(1):15-20
pubmed: 16616387
Arch Otolaryngol. 1983 Nov;109(11):746-9
pubmed: 6639443
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2579-90
pubmed: 25128401
Sci Rep. 2017 Dec 19;7(1):17805
pubmed: 29259311
JAMA Oncol. 2017 Nov 1;3(11):1487-1494
pubmed: 28542679
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):819-23
pubmed: 2323971
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Eur Arch Otorhinolaryngol. 2007 Apr;264(4):415-22
pubmed: 17102957
Eur J Cancer Care (Engl). 2014 May;23(3):401-12
pubmed: 24467393
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
J Thorac Oncol. 2013 May;8(5):543-8
pubmed: 23529191
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544